Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NIH-Developed Candidate Dengue Vaccine Shows Promise in Early-Stage Trial

Published: Monday, April 29, 2013
Last Updated: Monday, April 29, 2013
Bookmark and Share
The trial results appeared in the April 1 issue of the Journal of Infectious Diseases.

A candidate dengue vaccine developed by scientists at the National Institutes of Health has been found to be safe and to stimulate a strong immune response in most vaccine recipients, according to results from an early-stage clinical trial sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH.

Dengue fever, prevalent in many tropical and subtropical regions of the world, is caused by any of four related viruses - DENV-1, DENV-2, DENV-3 and DENV-4 - that are transmitted to humans by Aedes mosquitoes.

The World Health Organization estimates that every year, 50 million to 100 million cases of dengue occur worldwide, resulting in 500,000 hospitalizations of patients with severe disease, many of them in children.

Infection with one dengue virus results in immunity to that specific virus but not to the other three. Research shows that the likelihood of severe disease increases when a person is subsequently infected with a different dengue virus.

This observation suggests that the ideal dengue vaccine would be tetravalent - that is, protective against all four dengue viruses.

"The global burden of dengue is enormous - and it is growing," said NIAID director Anthony S. Fauci, M.D. "We are cautiously optimistic about these recent clinical trial results with this candidate tetravalent vaccine developed at NIAID; however, much more work still needs to be done."

The Phase I clinical trial (http://clinicaltrials.gov/ct2/show/NCT01072786), launched in July 2010 and led by principal investigator Anna Durbin, M.D., at Johns Hopkins Bloomberg School of Public Health in Baltimore, tested a single dose of each of four versions of the investigational dengue vaccine TetraVax-DV.

The vaccine was developed by scientists in NIAID's Laboratory of Infectious Diseases. It is a live-attenuated vaccine, which means that the viruses it contains are weakened enough such that they do not cause illness but still can induce an immune response. Each of the four vaccines tested included different mixtures of components designed to protect against all four dengue viruses.

The Phase I study was conducted in Baltimore; Burlington, Vt.; and Washington, D.C. The final study analysis included 112 healthy men and women ages 18 to 50 years who had not previously been exposed to dengue or related viruses such as West Nile virus and yellow fever virus.

Participants were randomized into four groups. In each group, 20 volunteers received a single 0.5-milliliter subcutaneous (under the skin) injection of one of the tetravalent candidate vaccine combinations, and eight others received placebo.

All were monitored for immediate adverse reactions for at least 30 minutes after vaccination, and subsequently took their body temperatures three times daily for 16 days to check for possible adverse reactions.

Participants also received a physical exam every other day up to Study Day 16, and then again on study days 21, 28, 42 and 180, when blood tests were also performed.

The researchers found that all four candidate vaccine combinations induced antibody responses against each of the dengue viruses. However, one vaccine combination, TV003, appeared to induce the most balanced antibody response against the dengue viruses.

A single dose of TV003 resulted in an antibody response to all four dengue viruses in 45 percent of participants and against three of the four viruses in an additional 45 percent. Overall, an immune response to at least three viruses was seen in 90 percent of vaccinees given TV003.

"What is promising about TV003 is that it elicited solid antibody responses after just one dose," explained Stephen Whitehead, Ph.D., of NIAID's Laboratory of Infectious Diseases, who led the development of the vaccine candidates. "Other vaccines in development require two or three injections at higher doses to achieve similar results."

All four candidate tetravalent vaccines were found to be safe, and no participants experienced fever or dengue-like illness after vaccination. The most common side effect was a faint rash (in 64 percent of vaccinees and none of the placebo recipients) consisting of small, non-painful bumps on the arms and torso that resolved within five to seven days.

The presence of the rash appeared to correlate with being white and having a stronger immune response to vaccination, according to the researchers. Ninety percent of white vaccinees experienced a vaccine-related rash while only 35 percent of African-American vaccinees developed a rash.

Further, 97 percent of white vaccine recipients (42 of 43) developed antibodies to at least three of the dengue viruses, compared with 60 percent of African-American vaccine recipients (22 of 37). It is unclear what caused this difference, but previous studies of severe dengue outbreaks in Brazil, Cuba and Haiti suggest that black people may have some inherent protection from dengue infection.

Alternatively, unknown factors may have resulted in a weaker antibody response to the vaccine among African-American participants. Additional research to evaluate racial differences in dengue infection and antibody response rates to dengue vaccines is needed, the authors wrote.

"The results of this Phase I dengue vaccine study look very promising, and NIAID scientists and their partners are pursuing further development of TV003," said Kathryn Zoon, Ph.D., director of NIAID's Division of Intramural Research.

The researchers are conducting studies to further evaluate the vaccine's safety and ability to stimulate an immune response in healthy volunteers (http://www.clinicaltrials.gov/ct2/show/NCT01436422) and in people who have been infected previously (http://www.clinicaltrials.gov/ct2/show/NCT01506570) by dengue or related viruses.

TV003's inexpensive production cost - less than $1 per dose - is critical to its potential use in developing countries, noted Dr. Whitehead. Manufacturers in Brazil, India and Vietnam - countries where dengue is prevalent - have licensed the vaccine technology for production and further evaluation. Phase II trials to evaluate the safety of TV003 (http://www.clinicaltrials.gov/ct2/show/NCT01696422) and its capacity to create an immune response will begin soon in Brazil and Thailand.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More Than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Exploring the Genome of the River Blindness Parasite
Researchers have decoded the genome of the parasite that causes the skin and eye infection known as river blindness.
Wednesday, December 07, 2016
Gene-Editing Improves Vision in Blind Rats
Scientists developed a targeted gene-replacement technique that can modify genes in both dividing and non-dividing cells in living animals.
Wednesday, December 07, 2016
Uncovering Cerebral Malaria’s Deadly Agents
NIH scientists film inside mouse brains to uncover biology behind the disease.
Wednesday, December 07, 2016
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Wednesday, November 30, 2016
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Wednesday, November 30, 2016
Antibody Protects Mice from Zika Infection
Researchers develop human-derived antibody protected pregnant mice and their developing fetuses from Zika infection.
Wednesday, November 23, 2016
Food Additives Promote Inflammation, Colon Cancer
Dietary emulsifiers promoted colon cancer in a mouse model by altering gut microbes and increasing gut inflammation.
Wednesday, November 23, 2016
Protein-Folding Gene Helps Heal Wounds
Researchers identified a protein that dramatically accelerates wound healing in animal models.
Wednesday, November 23, 2016
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Monday, November 21, 2016
Big Data for Infectious Disease Surveillance
NIH-led effort examines use of big data from health records and other digital sources for uses in infectious disease surveillance.
Tuesday, November 15, 2016
Potential Therapies Against Drug-Resistant Bacteria Identified
Researchers create new identification method for drug and drug combinations that may combat resistant infections.
Thursday, November 10, 2016
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Tuesday, November 08, 2016
Genetic Markers Predict Malaria Treatment Failure
By comparing 297 parasite genomes to a reference malaria parasite genome, researchers have identified two genetic markers that are strongly associated with the parasites’ ability to resist piperaquine.
Monday, November 07, 2016
Cannabinoid Receptor Structure Revealed
Scientists provided a detailed view of the primary molecule through which cannabinoids exert their effects on the brain. The findings might help guide the design of more targeted medicines with fewer side effects.
Wednesday, November 02, 2016
NIH Researchers Unveil New Wound-Healing Role for Protein-Folding Gene in Mice
The study found that topical treatment of an Hsp60-containing gel dramatically accelerates wound closure in a diabetic mouse model.
Friday, October 28, 2016
Scientific News
Big Genetics in BC: The American Society for Human Genetics 2016 Meeting
Themes at this year's meeting ranged from the verification, validation, and sharing of data, to the translation of laboratory findings into actionable clinical results.
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
Automated Low Volume Dispensing Trends
Gain a better understanding of the current and future market requirements for fully automated LVD systems.
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Diabetes Missing Link Discovered
Researchers from the University of Auckland have shown that beta catenin plays a vital role in the control of insulin release from the pancreas.
Study Reveals New Role for Hippo Pathway in Suppressing Cancer Immunity
Hippo pathway signaling regulates organ size by moderating cell growth, apoptosis and stem cell renewal, but dysregulation contributes to cancer development.
Biological Link between the Gut Microbiome and Parkinson’s Disease
The findings suggest that targeting the gut microbiome may provide a new approach for diagnosing and treating Parkinson’s disease.
How the Brain Recognizes Faces
Machine-learning system spontaneously reproduces aspects of human neurology.
Boosting Effectiveness of Asthma Therapy
A team of scientists from UCSF has developed a new treatment to dampen bronchospasm.
Improved Stability, Shelf Life of Protein Drugs
Study improves protein drug stability and extend their shelf life by tested a novel route for non-covalent protein modification.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!